Loading...
XSHE300147
Market cap878mUSD
Jan 13, Last price  
9.78CNY
1D
-1.71%
1Q
12.16%
Jan 2017
-23.09%
IPO
-45.42%
Name

Xiangxue Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300147 chart
P/E
—
P/S
2.80
EPS
—
Div Yield, %
2.18%
Shrs. gr., 5y
1.01%
Rev. gr., 5y
-1.69%
Revenues
2.30b
+5.13%
258,307,517294,808,980378,633,317513,383,583616,090,220801,020,2121,261,114,6511,523,980,1381,464,604,8421,862,087,8732,187,317,4382,504,252,3472,786,199,5163,072,090,6552,970,575,8412,187,069,9012,299,287,682
Net income
-389m
30,780,82935,950,73050,916,52874,199,46883,496,930107,167,519158,242,572196,796,127177,297,88466,024,14465,939,17856,439,310126,129,566141,797,31600-388,963,842
CFO
263m
+15.86%
138,016,02155,723,41746,186,86345,465,55829,553,113118,907,426328,367,622165,580,270159,890,412198,481,275109,533,18491,238,23583,019,533257,180,838257,562,269227,377,262263,441,902
Dividend
Jun 23, 20200.046 CNY/sh
Earnings
Jun 06, 2025

Profile

Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, procurement, manufacture, delivery, and distribution of pharmaceutical products in China. It offers antivirotic oral liquids under the Xiangxue brand name; and healthcare supplements, as well as health solutions, such as food and beverage. Xiangxue Pharmaceutical Co., Ltd. has strategic partnership agreement with 111, Inc. to develop the Internet + Medicine model for China's traditional Chinese medicine industry. The company was founded in 1997 and is based in Guangzhou, China.
URL
https://www.xphcn.com/
IPO date
Dec 15, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,299,288
5.13%
2,187,070
-26.38%
Cost of revenue
1,900,265
2,160,595
Unusual Expense (Income)
NOPBT
399,023
26,475
NOPBT Margin
17.35%
1.21%
Operating Taxes
12,795
Tax Rate
3.21%
NOPAT
386,228
26,475
Net income
(388,964)
 
Dividends
(140,650)
Dividend yield
4.14%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,842,028
2,006,057
Long-term debt
625,839
476,769
Deferred revenue
60,425
60,352
Other long-term liabilities
144,925
170,060
Net debt
2,140,072
1,844,293
Cash flow
Cash from operating activities
263,442
227,377
CAPEX
(56,034)
Cash from investing activities
(53,657)
379,262
Cash from financing activities
(200,629)
FCF
538,586
1,668,591
Balance
Cash
149,317
166,629
Long term investments
178,478
471,904
Excess cash
212,830
529,180
Stockholders' equity
1,049,795
1,174,857
Invested Capital
4,738,684
4,943,725
ROIC
7.98%
0.44%
ROCE
8.04%
0.48%
EV
Common stock shares outstanding
659,261
658,719
Price
5.15
-15.16%
6.07
-24.78%
Market cap
3,395,193
-15.09%
3,998,422
-24.78%
EV
5,923,781
6,255,763
EBITDA
636,321
268,772
EV/EBITDA
9.31
23.28
Interest
237,059
213,201
Interest/NOPBT
59.41%
805.29%